Comments
SMS Pharmaceuticals on Thursday announced the successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The inspection was conducted by the USFDA at its API facility Kandivalasa, Andhra Pradesh, during January 13-17. This facility predominantly caters to regulated markets including the US, it said. Shares of SMS Pharma slumped 8 per cent at ₹34.40 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.